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Abstract. In silico study was performed to predict the possibility of 1-benzyl-3-benzoylurea 
and 22 analogs as anticancer drug candidates, via VEGFR2 inhibition. Molecular docking 
studies against VEGFR2 receptor revealed that all of designed compounds have better score 
than the lead compound, of which three analogs (p-nitro, p-methoxy, and p-ethyl) were 
considered optimal among other compounds (< -90 kcal mol
‒1
). However, this result was not 
comparable to lenvatinib, which acts as native ligand of the receptor (-118.62 kcal mol
‒1
). 
Docking poses analysis showed that 1-benzyl-3-benzoylurea analogs failed to completely 
occupy VEGFR2 binding site. Therefore, it is argued that this has caused the non-optimal 
docking score of designed compounds. Furthermore, these compounds passed five different 
drug-likeness criteria successfully and were predicted to be orally bioavailable in rat. 
Ultimately, most of the analogs were predicted to have good ADMET characteristics, notably 
in terms of GI absorption and the absence of P-gp interaction, and low toxicity in rat. This 
study can be used as a starting point to validate this model by synthesis, in vitro and in vivo 
assay to validate the activity of 1-benzyl-3-benzoylurea and its analogs as potential anticancer 
candidate.  
Keywords: Anticancer candidate, arylurea derivatives, in silico study, VEGFR-2 inhibitor. 
1. Introduction 
Cancer is a terminology which is commonly used to describe the abnormality in cell growth and 
division [1]. In 2012, the number of population with cancer has reached 14.1 × 10
6
 people, with       
8.2 × 10
6
  mortality [2]. In Indonesia itself, the prevalence of cancer is 1.4 % of total population [3]. 
Hydroxyurea has been used for decades and still possesses valuable therapeutic activity against several 
type of cancer. This hydrophilic compund is distributed evenly in the human body fluid. Under 
physiologic condition (pH 7.4), the majority ofhydroxyurea will undergo ionization, thus reducing its 
ability to penetrate biological membrane. This condition will significantly diminished its biological 
activity [4].  
Several analog of urea based compounds have been widely developed, one of which is arylurea. 
Numerous studies suggested that this modification showed potential anticancer activity. Furthermore, 
preliminary study has proven the anticancer activity of 1-benzyl-3-benzoylurea, one of the analog of 
benzoylurea. This compound inhibits the growth of MCF-7 cell culture in breast cancer better than 
hydroxyurea [5]. Based on the finding, it can be concluded that 1-benzyl-3-benzoylurea is potential to 
be further developed as anticancer agent. This premise is supported by the number of anticancer drugs 
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in the market which contain arylurea functional group, such as sorafenib and lenvatinib. These two 
compounds are known to act as VEGFR-2 inhibitor [6, Topliss in 7] (figure 1).  
This research aimed to explore the possibility to improve the anticancer activity of 1-benzyl-3-
benzoylurea analogs using in silico method. Several novel compounds were designed and predicted 
their activity using molecular docking against VEGFR-2. Furthermore, the drug-likeness and ADMET 
properties of those compounds were also evaluated. 
2. Materials and methods 
2.1. Preparation of 1-benzyl-3-benzoylurea analogs 
Total of 23 novel analogs of 1-benzyl-3-benzoylurea were designed by implementing Topliss scheme 
[Topliss in 7], of which the steric and electronic properties of every substituent were taken into 
account. These compounds were drawn in 2D format (MarvinSketch 16.8.1) 
(http://www.chemaxon.com) and then transformed into 3D structure using semiempirical method of 
AM1 [8] available in MOPAC2016 (http://openmopac.net/MOPAC2016.html). 
 
 
(a) (b) 
Figure 1. Chemical structure of 1-Benzyl-3Benzoylurea (a) and lenvatinib (b). 
2.2. Preparation of protein 
VEGFR-2 protein was obtained from Brookhaven Protein Data Bank (PDB) 
(https://www.rcsb.org/pdb/) with PDB ID of 3WZD. This protein was chosen since it is complexed 
with lenvatinib, an arylurea analog [6]. Hydrogen atom was then added, followed by the assignment of 
Amber ff14SB partial charge [9]. Correction of sidechain residue was also performed by employeeing 
the most recent Dunbrack rotamer library [10]. The purpose of this step was to reconstruct the missing 
information of amino acid sidechain. Lenvatinib was also prepared by adding hydrogen atom. The 
whole process was performed using Chimera 1.13 [11]. 
2.3. Molecular docking 
Molegro Virtual Docker 5.0 (Molegro ApS, 2013) was applied to evaluate the interaction of designed 
compounds with VEGFR-2.  
2.4. ADMET and drug-likeness evaluation 
Drug candidates should possess favorable ADME properties and ideally non-toxic. Therefore, the 
designed compounds were evaluated of their ADME profile, including drug-likeness, partition 
coefficient, solubility, and several other parameters using SwissADME [12] module provided in SIB 
(Swiss Institute of Bioinformatics) webserver (https://www.sib.swiss). Furthermore, the toxicity aspect 
of designed compound was also predicted using webserver ProTox [13] (https://tox.charite.de).  
3. Results 
3.1. Molecular docking 
Molecular docking was performed to evaluate the interaction mode of designed compounds against 
VEGFR-2 and to assess the magnitude of interaction between them. Similar study have been 
performed [14] using similar receptor, albeit complexed with different arylurea analog [15]. This study 
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was conducted in order to verify the previous result using slightly modified method. Docking method 
needs to be validated by redocking the native ligand to the protein prior to the usage [16]. Based on 
redocking result of lenvatinib to its protein [6], RMSD result of 0.7 was obtained. This implies that the 
docking method used is able to predict the ligand orientation accurately. Docking method selected in 
this study was simplex evolution as pose generator which was evaluated using grid based MolDock 
score [17]. The findings showed that no designed compounds performed better than native ligand, in 
terms of docking score (table 1).    
Docking pose analysis of three best performing analogs (Compound 11, 22, and 23) showed the 
dissimilarity of binding mode compared to Lenvatinib. Similarity is only observed in the urea moiety 
of both compound, which is with Glu 885 and Asp 1046. Lenvatinib as the newly discovered VEGFR-
2 inhibitor classified as type V inhibitor, interact in a similar way with Sorafenib as the older, type II 
VEGFR-2 inhibitor [6, Topliss in 7]. Therefore, the pharmacophore motive for Sorafenib-like, type II 
VEGFR-2 inhibitor [18] could also be applicable for type V inhibitor. However, docking pose of all 
designed compounds showed occupation only in the RDP (Regulatory Domain Pocket) area. While 
type II inhibitor and Lenvatinib also occupy ATP binding domain. This made the docking score of 1-
benzyl-3benzoylurea analogs are higher than lenvatinib and sorafenib [14] (figure 2). 
3.2. ADMET and drug-likeness evaluation 
SwissADME provides detail and extensive physicochemical profile, ADME, and medicinal chemistry 
property of a compound. Regarding the physicochemical aspect, two parameters (partition coefficient 
and solubility) are considered to play important roles. Based on predicted LogP value, it is concluded 
that all of designed compounds lies within the range value of 1.6 to 3.6. Eventhough LogP value does 
not always correspond to certain ADME aspect, this parameter could depict the probability of a 
compund as drug candidate, where in this case all 23 compunds possess such quality to be considered 
as drug-like [19]. SwissADME LogP value was calculated from five different algorithm, therefore it is 
assumed that the value represents real condition [12]. On the other hand, solubility prediction was 
carried out using three different method with the output of LogS value. Generally, the designed 
compounds are predicted to have optimum water solubility, even if there was a slightly different result 
among the method. The most obvious difference was observed in SILICOS-IT (http://silicos-it.be.s3-
website-eu-west-1.amazonaws.com/software/filter-it/1.0.2/filter-it.html) method since it employs 
fragment-based approach in LogS calculation, while the other methods [20, 21] based on complete 
molecular topology (table 2). 
 
Figure 2. Docking pose superposition of one of 1-Benzyl-3-Benzoylurea analogs (compound 23) 
(light blue) with Lenvatinib (gray). It showed a dissimilarity in binding mode between those         
                         
two compounds, notably in urea moiety (highlighted). 
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Table 1. Docking score of 1-Benzyl-3-Benzoylurea and its analogs against VEGFR-2. 
 
 
Code Compound Substituents 
Docking Score 
(kcal mol
‒1
) 
1 1-benzyl-3-benzoylurea R1=H;R2=H;R3=H -73.95 
2 1-benzyl-3-(2-chloro)-benzoylurea R1=Cl;R2=H;R3=H -76.92 
3 1-benzyl-3-(3- chloro)-benzoylurea R1=H;R2=Cl;R3=H -80.38 
4 1-benzyl-3-(4-chloro)-benzoylurea R1=H;R2=H;R3=Cl -81.71 
5 
1-benzyl-3-(2,4-dichloro)-
benzoylurea 
R1=Cl;R2=H;R3=Cl  -79.14 
6 
1-benzyl-3-(3,4-dichloro)-
benzoylurea 
R1=H;R2=Cl;R3=Cl  -79.83 
7 
1-benzyl-3-(4-chloromethyl)-
benzoylurea 
R1=H;R2=H;R3=CH2Cl -75.48 
8 
1-benzyl-3-(3-chloromethyl)-
benzoylurea 
R1=H;R2=CH2Cl;R3=H  -87.19 
9 
1-benzyl-3-(2- chloromethyl)-
benzoylurea 
R1=CH2Cl;R2=H;R3=H  -79.72 
10 1-benzyl-3-(4-methyl)-benzoylurea R1=H;R2=H;R3=CH3  -74.15 
11 1-benzyl-3-(4-ethyl)-benzoylurea R1=H;R2=H;R3=C2H5  -90.73 
12 1-benzyl-3-(3-ethyl)-benzoylurea R1=H;R2=C2H5;R3=H  -78.99 
13 1-benzyl-3-(2-ethyl)-benzoylurea R1=C2H5;R2=H;R3=H  -78.6 
14 1-benzyl-3-(4-propyl)- benzoylurea R1=H;R2=H;R3=C3H7  -83.51 
15 
1-benzyl-3-(4-t-butyl)- 
benzoylurea 
R1=H;R2=H;R3=C(CH3)3 -69.76 
16 1-benzyl-3-(4-fluoro)-benzoylurea R1=H;R2=H;R3=F  -82.21 
17 
1-benzyl-3-(2-trifluoromethyl)-
benzoylurea 
R1=CF3;R2=H;R3=H -81.13 
Continue to the next page. 
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Code Compound Substituents 
Docking Score 
(kcal mol
‒1
) 
18 1-benzyl-3-(3-trifluoromethyl)-
benzoylurea 
R1=H;R2=CF3;R3=H -87.26 
19 
1-benzyl-3-(4-trifluoromethyl)-
benzoylurea 
R1=H;R2=H;R3=CF3  -79.78 
20 1-benzyl-3-(4-bromo)-benzoylurea R1=H;R2=H;R3=Br -76.53 
21 
1-benzyl-3-(4- bromomethyl)- 
benzoylurea 
R1=H;R2=H;R3=CH2Br  -74.34 
22 1-benzyl-3-(4- nitro)-benzoylurea R1=H;R2=H;R3=NO2  -95.2 
23 
1-benzyl-3-(4- methoxy)-
benzoylurea 
R1=H;R2=H;R3=OCH3  -90.91 
Lenvatinib -118.62 
 
ADME prediction showed that the analog compounds possess several favorable ADME properties. 
Based on ratio of WlogP to tPSA [22], all of the compound was predicted to have good absorption in 
GIT and 22 of which could penetrate blood-brain barrier. Analog with nitro substituent possesses the 
lowest partition coefficient, hence too hydrophyllic to penetrate blood-brain barrier. Surprisingly, there 
is no single compound which has a tendency to act as P-gp substrate. P-glycoprotein, a macromolecule 
found to be overexpressed in multi-drug resistant cancer, has an important role in transporting 
xenobiotics out from cell [23]. Therefore, this finding indicates that 1-benzyl-3-benzoylurea scaffold 
could be used as potential anticancer agent. Furthermore, SwissADME also enable one to predict the 
possible occurrence of CYP450-mediated biotransformation. The result showed that the majority of 
compound interacts with at least one of the five isoforms, where two of the analogs (4-propyl and 4-
bromomethyl) would interact with four out of five isoforms. On the contrary, three of the analogs (4-
fluoro, 4-nitro, and 4-methoxy) along with the parent compound possibly would not interact with any 
of the CYP450 isoforms. It is also concluded that 1A2 and 2C19 are the major isoform which would 
become the target of most of the analogs, while no interaction is predicted to happen with 3A4   
(figure 3).  
Drug-likeness is a key criteria in screening drug candidates at the earlier phase of drug discovery 
and development. This parameter can be described as a mean to correlate physicochemical aspect of a 
compound with its biopharmaceutical aspect in human body, especially its influence in bioavailability 
of per oral route [24]. Based on five commonly used drug-likeness criteria applied in the webserver 
[12], 1-benzyl-3-benzoylurea with its 22 analogs are considered to pass all of them, thus can be 
categorized as drug-like compounds. In addition, evaluation was also carried out using ABS criteria 
[25], where all of the compounds obtained the value of 0.55. This criteria is based on the probability 
value of a compound to possess optimum profile of bioavailability and permeability, where value of 
0.55 implies the obedience of Lipinski rule of five [26] and 55 % probability of rat bioavailability 
value higher than   10 %. 
In addition, detection of structural alert [27] was performed in order to identify whether the 
designed compound possess problematic functional group, which could lead to a toxicity, 
mutagenicity, or metabolic instability. It showed that five of designed compounds possess indesirable 
moiety (alkyl halide and nitroarene). Studies have indicated the reactivity of compounds containing 
such functional groups, which lead to carcinogenic, mutagenic, and hepatotoxic effect [28]. This 
Table 1. Continued. 
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criteria could be used as preliminary alert to give more attention to the activity and toxicity in 
developing 1-benzyl-3-benzoylurea scaffold [29]. 
Table 2. Water solubility prediction of 1-Benzyl-3-Benzoylurea and its analogs. 
Compounds 
LogP Water Solubility 
(Consensus LogP) LogS (ESOL) LogS (Ali) LogS (SILICOS-IT) 
1 2.16 Soluble Soluble Moderately Soluble 
2 2.79 Soluble Moderately Soluble Moderately Soluble 
3 2.74 Soluble Moderately Soluble Moderately Soluble 
4 2.73 Soluble Moderately Soluble Moderately Soluble 
5 3.32 Moderately Soluble Moderately Soluble Poorly Soluble 
6 3.26 Moderately Soluble Moderately Soluble Poorly Soluble 
7 2.8 Soluble Moderately Soluble Poorly Soluble 
8 2.77 Soluble Moderately Soluble Poorly Soluble 
9 2.78 Soluble Moderately Soluble Poorly Soluble 
10 2.59 Soluble Moderately Soluble Moderately Soluble 
11 2.86 Soluble Moderately Soluble Poorly Soluble 
12 2.86 Soluble Moderately Soluble Poorly Soluble 
13 2.89 Soluble Moderately Soluble Poorly Soluble 
14 3.25 Moderately Soluble Moderately Soluble Poorly Soluble 
15 3.55 Moderately Soluble Moderately Soluble Poorly Soluble 
16 2.55 Soluble Soluble Moderately Soluble 
17 3.24 Moderately Soluble Moderately Soluble Poorly Soluble 
18 3.29 Moderately Soluble Moderately Soluble Poorly Soluble 
19 3.27 Moderately Soluble Moderately Soluble Poorly Soluble 
20 2.79 Moderately Soluble Moderately Soluble Poorly Soluble 
21 2.92 Moderately Soluble Moderately Soluble Poorly Soluble 
22 1.62 Soluble Moderately Soluble Moderately Soluble 
23 2.23 Soluble Soluble Moderately Soluble 
 
Figure 3. Prediction of interaction of designed compounds with several CYP450 isoforms. 
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Ultimately, prediction of toxicity using ProTox [13] showed that the designed compound are 
predicted to have oral LD50 value ranging from 818 mg kg
‒1
 to 3 000 mg kg
‒1
 in rat model, with 
analogs of p-methyl and p-trifluoromethyl bearing the lowest value and four analogs (o-chloro,               
o-chloromethyl, m-chloromethyl, and o-trifluoromethyl) bearing the highest one. It was also observed 
that the substituent position in aromatic could significantly affect the predicted value of LD50 as was 
shown in the case of trifluoromethyl (vide supra).  
4. Conclusion 
Molecular docking study showed that three of 1-benzyl-3-benzoylurea analog (p-nitro, p-methoxy, and 
p-ethyl) possess better docking score among the other analogs with the value around -90 kcal mol
‒1
. 
However, there is no single compound which performs better than Lenvatinib (-118.62 kcal mol
‒1
) due 
to the inability of all designed compound to completely occupy the VEGFR-2 binding site. This 
hypothesis would be used as a foundation which needs to be proven via in vitro assay in the future. 
Furthermore, it can be implied that the majority of compound have good physicochemical profile with 
several other ADMET properties, notably in terms of P-gp interaction. Nevertheless, the identification 
of several analogs with problematic moiety, should be noted in order to develop more safe and potent 
anticancer agent based on 1-benzyl-3-benzoylurea scaffold. 
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